- Home
- DEA vs RCKT Comparison
DEA vs RCKT Comparison
Compare DEA & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- RCKT
- Stock Information
- Founded
- DEA 2011
- RCKT 1999
- Country
- DEA United States
- RCKT United States
- Employees
- DEA N/A
- RCKT N/A
- Industry
- DEA Real Estate Investment Trusts
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- RCKT Health Care
- Exchange
- DEA Nasdaq
- RCKT Nasdaq
- Market Cap
- DEA 844.3M
- RCKT 764.5M
- IPO Year
- DEA 2015
- RCKT N/A
- Fundamental
- Price
- DEA $20.23
- RCKT $7.18
- Analyst Decision
- DEA Hold
- RCKT Strong Buy
- Analyst Count
- DEA 4
- RCKT 10
- Target Price
- DEA $29.06
- RCKT $44.10
- AVG Volume (30 Days)
- DEA 878.1K
- RCKT 3.2M
- Earning Date
- DEA 04-29-2025
- RCKT 05-08-2025
- Dividend Yield
- DEA 4.80%
- RCKT N/A
- EPS Growth
- DEA N/A
- RCKT N/A
- EPS
- DEA 0.41
- RCKT N/A
- Revenue
- DEA $314,385,000.00
- RCKT N/A
- Revenue This Year
- DEA $6.87
- RCKT N/A
- Revenue Next Year
- DEA $7.97
- RCKT N/A
- P/E Ratio
- DEA $49.14
- RCKT N/A
- Revenue Growth
- DEA 6.82
- RCKT N/A
- 52 Week Low
- DEA $19.33
- RCKT $4.55
- 52 Week High
- DEA $36.31
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- DEA 36.84
- RCKT 46.92
- Support Level
- DEA $19.86
- RCKT $6.21
- Resistance Level
- DEA $21.33
- RCKT $8.26
- Average True Range (ATR)
- DEA 0.71
- RCKT 0.58
- MACD
- DEA 0.19
- RCKT 0.03
- Stochastic Oscillator
- DEA 44.97
- RCKT 28.05
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.